Our investments


Deinobiotics was founded in 2009 by Deinove, (Truffle Capital portfolio), with the support of OSEO-ERDF. Deinobiotics is a subsidiary dedicated to the research and development of antibiotics and antifungals. The current R&D program targets mainly antibiotics capable of fighting against resistant hospital germs responsible for nosocomial infections (gram-negative bacteria and fungi).

Antoine Pau is a member of the Board of Directors.